CTPI-2
Product Specifications
UNSPSC Description
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity[1][2].
Target Antigen
Mitochondrial Metabolism
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ctpi-2.html
Purity
99.95
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CC=CC=C1NS(=O)(C2=CC=C(Cl)C([N+]([O-])=O)=C2)=O
Molecular Weight
356.74
References & Citations
[1]Tan M, et al. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ. 2020;27(7):2143-2157.|[2]Fernandez HR, et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 2018;25(7):1239-1258.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-123986/CTPI-2-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-123986/CTPI-2-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
68003-38-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
